Scarica l'app Stockscreener
40.20
1.65%
0.76
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Cogent Biosciences Inc Borsa (COGT) Ultime notizie
Cogent Biosciences (COGT) director takes options in lieu of cash - Stock Titan
Enterprise value to revenue forward of Cogent Biosciences, Inc. – NASDAQ:COGT - TradingView
3 Reasons Cogent Biosciences (COGT) Looks Pricey After Its FDA Filing - Sahm
COGTCogent Biosciences Inc Forecast, Target Price - Finviz
How (COGT) Movements Inform Risk Allocation Models - Stock Traders Daily
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Advanced Systemic Mastocytosis - Investing News Network
Cogent Biosciences Submits US FDA New Drug Application for Potential Mast Cell Disease Treatment - marketscreener.com
Cogent Biosciences (COGT) Submits NDA to FDA for Bezuclastinib - GuruFocus
Cogent seeks FDA approval for rare blood disease drug - Stock Titan
Why Cogent Biosciences (COGT) Is Up 6.7% After Russell Index Removal Reshapes Its Investor Base - simplywall.st
Cogent Biosciences stock retreats after recent gains as bullish momentum consolidates - Traders Union
Cogent Biosciences stock edges lower with sideways action after Elevation Summit event - Traders Union
Cogent Biosciences, Inc.(NasdaqGS: COGT) dropped from Russell 2000 Value Benchmark - marketscreener.com
Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Cogent Biosciences, Inc. Actuals & Estimates (NASDAQ:COGT) - TradingView
Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Cogent Biosciences, Inc.(NasdaqGS: COGT) dropped from Russell Microcap Index - marketscreener.com
Cogent Biosciences, Inc.(NasdaqGS: COGT) dropped from Russell 3000E Index - marketscreener.com
Cogent Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Ros Matthew - Moomoo
Cogent Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Shegog Todd - Moomoo
Cogent Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Robbins Andrew R - Moomoo
COGT Forecast — Price Target — Prediction for 2027 - TradingView
Cogent (COGT) Presents Preclinical Data for Novel JAK2 Inhibitor CGT1145 at 2026 EHA Congress - Insider Monkey
Is Cogent Biosciences (COGT) ’s New Cancer Drug 100 Times More Precise Than What’s Already on the Market? - Yahoo Finance
New Bezuclastinib and JAK2 Data Could Be A Game Changer For Cogent Biosciences (COGT) - Sahm
Trading Systems Reacting to (COGT) Volatility - Stock Traders Daily
H.C. Wainwright Sticks to Its Buy Rating for Cogent Biosciences (COGT) - The Globe and Mail
H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Cogent Biosciences Inc (COGT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cogent Biosciences Inc (COGT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cogent Biosciences Inc (COGT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cogent Biosciences Inc (COGT) Institutional Confidence - TradingKey
Cogent Biosciences Inc (COGT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cogent Biosciences Inc (COGT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cogent Biosciences Inc (COGT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cogent Biosciences (COGT) Gains 1.92% as Biotech Sector Momentum BuildsLeveraged ETF Flow - Město Břeclav
Cogent Biosciences Inc (COGT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cogent Biosciences Inc (COGT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Stifel reiterates Cogent stock Buy rating after trial data - Investing.com UK
Stifel reiterates Cogent stock Buy rating after trial data By Investing.com - Investing.com India
Stifel Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage (NASDAQ:COGT) - Seeking Alpha
Cogent Biosciences, Inc. (COGT) Presents at European Hematology Association (EHA) 2026 CongressSlideshow - Seeking Alpha
Cogent Biosciences' Potential Rare Blood Disease Treatment Meets Endpoints in Clinical Trial - Moomoo
Cogent unveils positive preclinical data for JAK2 inhibitor CGT1145 - grafa.com
Cogent Gallops on Data Release - Baystreet.ca
Cogent Biosciences unveils pivotal APEX trial data at EHA 2026 - grafa.com
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association Congress - Investing News Network
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association Congress - Investing News Network
Cogent Biosciences Announces Preclinical Data from Novel - GlobeNewswire
Cogent Biosciences Announces Detailed Data from Apex Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis - marketscreener.com
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress - The Manila Times
Director for Cogent Biosciences (NASDAQ: COGT) granted 17,901 stock options - Stock Titan
Cogent Biosciences (COGT) director receives 17,901 stock options at $31.98 strike - Stock Titan
Cogent Biosciences (COGT) director linked to option grant for funds - Stock Titan
Director at Cogent Biosciences (NASDAQ: COGT) receives 17,901 stock options - Stock Titan
Cogent Biosciences (COGT) director Arlene Morris receives grant of 17,901 stock options - Stock Titan
Cogent Biosciences (NASDAQ: COGT) 2026 meeting backs board, auditor and pay - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
How Investors May Respond To Cogent Biosciences (COGT) Priority Review For Bezuclastinib GIST Regimen - Yahoo Finance
Cogent Biosciences Inc Annual Shareholders Meeting Transcript - GuruFocus
COGT: All proposals, including director elections and auditor ratification, were approved - TradingView
Is Cogent Biosciences, Inc. (COGT) A Good Stock To Buy Now? - Insider Monkey
1.16%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):